2001
Impact of Clozapine Prescription on Inpatient Resource Utilization
SERNYAK M, ROSENHECK R, DESAI R, STOLAR M, RIPPER G. Impact of Clozapine Prescription on Inpatient Resource Utilization. The Journal Of Nervous And Mental Disease 2001, 189: 766-773. PMID: 11758660, DOI: 10.1097/00005053-200111000-00006.Peer-Reviewed Original ResearchConceptsInpatient resource utilizationClozapine treatmentInpatient daysComparison groupService utilization variablesMore inpatient daysClozapine prescriptionIndex dischargeRefractory schizophreniaConventional neurolepticsTypical neurolepticsClinical variablesVA databasesInpatient hospitalizationInpatient careYear treatmentUtilization variablesClozapineTreatmentNeurolepticsPatientsSchizophrenia
1999
Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia
Rosenheck R, Dunn L, Peszke M, Cramer J, Xu W, Thomas J, Charney D, Schizophrenia T. Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia. American Journal Of Psychiatry 1999, 156: 88-93. PMID: 9892302, DOI: 10.1176/ajp.156.1.88.Peer-Reviewed Original ResearchConceptsRefractory schizophreniaDeficit syndromeNegative symptomsPositive symptomsClozapine's effectVeterans Administration TrialEffects of clozapineImpact of clozapineNegative clinical symptomsProminent negative symptomsClozapine treatmentHospitalized patientsConventional medicationsClinical symptomsControl subjectsAdministration trialClinical subtypesAnalysis of covariancePatientsClozapineSyndromeSymptomsNegative syndromeSchizophreniaTime points
1998
Predictors of differential response to clozapine and haloperidol
Rosenheck R, Lawson W, Crayton J, Cramer J, Xu W, Thomas J, Stolar M, Charney D, Schizophrenia F. Predictors of differential response to clozapine and haloperidol. Biological Psychiatry 1998, 44: 475-482. PMID: 9777179, DOI: 10.1016/s0006-3223(98)00117-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntipsychotic AgentsClozapineDouble-Blind MethodDrug ResistanceFemaleHaloperidolHumansMalePsychiatric Status Rating ScalesQuality of LifeRacial GroupsSchizophreniaSchizophrenic PsychologySocial SupportTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsQuality of lifeThree-month outcomeOnset of schizophreniaSeverity of symptomsGreater symptom reductionGreater improvementRefractory patientsRefractory schizophreniaClozapine treatmentHospital daysClinical predictorsExtrapyramidal symptomsHospitalized patientsClinical trialsBaseline predictorsSample patientsSide effectsSymptom reductionClozapinePatientsSymptomsHigher symptomsHigh levelsHaloperidolMultiple regression analysis